EnLyteRX Invited to Present at Integrative Medicine for Mental Health Conference in San Diego

The 6th annual IMMH Conference attracted over 300 providers this year looking for new, integrative approaches.

EnLyte is a perfect fit for this meeting as the cutting-edge prescription folate with a broad range of uses. A prescription vitamin FDA-regulated to treat conditions related to folate deficiency and/or high homocysteine, EnLyte is widely used as monotherapy in mild depression and adjunctive therapy to an SSRI/SNRI in mild, moderate, and severe depression. EnLyte bypasses the most common MTHFR genetic polymorphisms found in depressive disorders. It is pregnancy category A and safe for use in children/adolescents.

Providers from all specialties are eager to have a natural, prescription product that clearly fills an umet need. According to the STAR*D Study, commonly used standard antidepressants produce low remission rates that can take several weeks at best.

Folate therapy is recommended by the  American Psychiatric Association 2010 Treatment Guidelines as an effective strategy for treating depression that has a favorable cost and side effect profile.

In a double-blind, placebo-controlled study submitted to The Journal of Clinical Psychiatry, 330 MTHFR-positive patients with Major Depressive Disorder obtained a 42% remission rate in 8 weeks with EnLyte monotherapy. EnLyte also reduced homocysteine by 33%, a toxic amino acid linked to dozens of diseases.

EnLyte is paid by many insurances plans with a $44 average copay nationwide and is $58 per month through mail order.

Contact EnLyte Customer Care at 985-788-7755 to obtain:

• Licensed prescriber samples & Key Opinion Leader teleconference schedules
• Full EnLyte clinical reprint/APA Guidelines
• Copay coupon cards
• Information on homocysteine